Use of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors in older patients with ER-positive HER2-negative breast cancer: Young International Society of Geriatric Oncology review paper

The current standard of care for the management of estrogen receptor (ER)-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer has been redefined by the introduction of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors. Although adults aged 65 years and older account for...

Descripción completa

Detalles Bibliográficos
Autores principales: Battisti, Nicolò Matteo Luca, De Glas, Nienke, Sedrak, Mina S., Loh, Kah Poh, Liposits, Gabor, Soto-Perez-de-Celis, Enrique, Krok-Schoen, Jessica L., Menjak, Ines B., Ring, Alistair
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6249663/
https://www.ncbi.nlm.nih.gov/pubmed/30479671
http://dx.doi.org/10.1177/1758835918809610

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6249663/
https://www.ncbi.nlm.nih.gov/pubmed/30479671
http://dx.doi.org/10.1177/1758835918809610

Ejemplares similares